Pipeline Insight: Small Molecule Targeted Cancer Therapies - New Targets Set to Drive Growth Now Available on ReportsandReports

ReportsandReports Announce it Will Carry Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth Market Research Report in its Store.

DALLAS, April 20, 2010 - Browse the complete Report on:
www.reportsandreports.com/market-reports/pipeline-insight-small-molecu
le-targeted-cancer-therapies-new-/

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Small molecule targeted therapies represent a highly lucrative class of
anticancer therapies with 12 drugs currently approved for various tumor
types. This promise of high commercial rewards has driven considerable
pipeline activity for small molecule targeted therapies within cancer.

    Scope

    - Examination of the small molecule targeted cancer therapies
      pipeline with in-depth clinical and commercial profiles of Phase
      III candidates

    - Seven major pharmaceutical market sales forecasts for Phase III
      pipeline products through to 2019 with product-specific assumptions

    - Segmentation and analysis of the current small molecule targeted
      cancer therapies pipeline by developmental phase, drug target and
      company

    - Insight and analysis of market potential including commercial
      opportunity and discussion of unmet needs

Highlights

There are currently 288 small molecule targeted therapies in development
for cancer. Single-target signal transduction inhibitors and multi-targeted
inhibitors form the majority of the pipeline, accounting for 28% and 28% of
the pipeline, respectively. These two classes each contain a number of agents
with novel mechanisms of action.

Progress in understanding of how to target tyrosine kinases with small
molecules has benefited oncology drug discovery. Efforts are continuing to
develop small molecule inhibitors against other kinases that are more
selective and capable of overcoming drug resistance. Around 30 distinct
targets are currently being tested in Phase I clinical trials.

The late-phase small molecule therapies directed towards novel targets
are forecast to generate sales of $3,635m by 2019 across the seven major
markets. Abiraterone (Cougar Biotechnology/Johnson & Johnson) and BSI-201
(BiPar Sciences/Sanofi-Aventis) are forecast to achieve the highest sales by
2019.

    Reasons to Purchase

    - Identify key drugs and companies within the small molecule targeted
      cancer therapies pipeline based on sales forecasts and Datamonitor
      drug assessment

    - Assess the shifting small molecule targeted cancer therapies market
      dynamic and how future treatment will incorporate pipeline products

    - Identify licensing opportunities based on company portfolio and
      market needs

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth
market research studies of over 5000 micro markets, and 25 industry specific
websites. Our client list boasts almost all well-known publishers of such
reports across the globe. We as a third-party reseller of market research
reports employ a number of marketing tools, such as press releases,
email-marketing and effective search-engine optimization techniques to drive
revenues for our clients. We also provide 24/7 online and offline support
service to our customers.

    Contact:
    Ms. Sunita
    7557 Rambler Road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    sales@reportsandreports.com
    www.reportsandreports.com/

Contact: Ms. Sunita, 7557 Rambler Road, Suite 727, Dallas, TX 75231, Tel: +1-888-989-8004,
sales at reportsandreports.com